B/Phuket/3073/2013-Like Virus (B/Singapore/Inftt-16-0610/2016, Wild Type), B/Austria/1359417/2021-Like Strain (B/Singapore/Wuh4618/2021), A/Darwin/6/2021(H3N2)-Like Strain (A/Darwin/11/2021, Wild Type), A/Wisconsin/67/2022 (H1N1)Pdm09-Like Strain (A/Georgia/12/2022 Cvr-167)

1 trials JAnti-infectives

Filter these 1 trials by condition, phase, country and more.

Open in Search →

1 Registered trials

0 Recruiting

1 Completed trials

1 Sponsors

21 Countries

Phase III

Phase III: 1

Indications tested

Multiple sclerosis relapse 1

Sponsors using this IMP

Novartis Pharma AG 1

All trials

1 total

An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Phase III 21 countries Novartis Pharma AG

Showing 1–1 of 1 trials

← All drugs A–Z